FDA authorizes lower disease risk claim for ZYN pouches
The FDA issued MRTP orders for 20 ZYN nicotine pouch variants, permitting Philip Morris to market them as lower-risk alternatives to cigarettes for specific diseases. The authorization includes postmarket surveillance requirements and expires in five years. This marks the first such designation for a nicotine pouch product.
*this image is generated using AI for illustrative purposes only.
The U.S. Food and Drug Administration (FDA) has issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products, authorizing Philip Morris International Inc. to market specific reduced-risk claims. This decision allows the company to state that using ZYN instead of cigarettes puts consumers at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorization provides science-based information to the more than 45 million legal-age nicotine consumers in America and reinforces the FDA's approach to evaluating products across the continuum of risk.
The FDA's determination confirms that the products, as used by consumers, would significantly reduce harm and the risk of tobacco-related disease while benefiting the health of the population as a whole. The authorized claim is effective immediately. The orders cover 10 ZYN varieties—Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen—each available in 3 mg and 6 mg nicotine strengths.
Authorized ZYN Variants
The FDA's MRTP orders cover a range of flavors and nicotine strengths. The following products are included in the authorization:
| Product Variant | Nicotine Strength |
|---|---|
| ZYN Cool Mint | 3 mg, 6 mg |
| ZYN Peppermint | 3 mg, 6 mg |
| ZYN Spearmint | 3 mg, 6 mg |
| ZYN Wintergreen | 3 mg, 6 mg |
| ZYN Citrus | 3 mg, 6 mg |
| ZYN Coffee | 3 mg, 6 mg |
| ZYN Cinnamon | 3 mg, 6 mg |
| ZYN Smooth | 3 mg, 6 mg |
| ZYN Chill | 3 mg, 6 mg |
| ZYN Menthol | 3 mg, 6 mg |
Authorization and Monitoring Requirements
As part of the authorization, Swedish Match company must conduct postmarket surveillance and research to assess consumer behavior and understanding of the modified risk information. The orders will expire in five years unless the company receives renewed authorization. The FDA emphasized that MRTP orders apply only to the specific products reviewed and do not extend to an entire class of tobacco products. The agency noted that it may withdraw the orders if continued marketing no longer benefits public health, including if youth uptake rises significantly.
To date, the FDA has authorized 26 nicotine pouch products after determining they meet the statutory public health standard. This is the first time a nicotine pouch has received the designation. Bret Koplow, acting director of the FDA’s Center for Tobacco Products, stated that the decision lets consumers "make informed choices."
Stacey Kennedy, Philip Morris U.S. CEO, highlighted that the authorization ensures adults have access to accurate, FDA-authorized evidence regarding the reduced risks of switching from cigarettes to ZYN. "Today’s news ensures these adults have access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer," Kennedy said.
How will this MRTP authorization impact Philip Morris International's market share relative to traditional tobacco products and competing nicotine pouch brands?
What specific metrics will the FDA monitor to determine if youth uptake rises significantly enough to withdraw the MRTP orders?
Could this decision set a regulatory precedent for other tobacco companies seeking MRTP authorization for alternative nicotine delivery systems?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
